Drug
Seladelpar clinical trials
Also written MBX-8025 and Livdelzi®.
- studies test it
- 15
- open now
- 3
- in phase 3
- 5
- first study started
- 2007
Keep track of what changes. Save the seladelpar studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 2 |
| 2023 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 8
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 1
Gilead Sciences (14) · University of California, San Diego (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses seladelpar is read from its arms, and is right about nine times in ten.
Testing it · 15
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingPhase 3Gilead SciencesNCT06051617Written as Seladelpar
- Study of Seladelpar and Cilofexor in Participants With Primary Biliary CholangitisNot yet recruitingPhase 2Gilead SciencesNCT07841977Written as Seladelpar
- Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).Not yet recruitingPhase 2University of California, San DiegoNCT07305363Written as Seladelpar
- Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)CompletedPhase 3Gilead SciencesNCT06060665Written as Seladelpar 10 mg
- Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)Active, not recruitingPhase 3Gilead SciencesNCT03301506Written as Seladelpar 5 mg Capsule
- An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)CompletedPhase 1Gilead SciencesNCT04950764Written as Seladelpar
- Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)TerminatedPhase 2Gilead SciencesNCT02609048Written as Experimental: Seladelpar 50 mg
- A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSCTerminatedPhase 2Gilead SciencesNCT04024813Written as Seladelpar
- RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)CompletedPhase 3Gilead SciencesNCT04620733Written as Seladelpar 10 mg
- A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)TerminatedPhase 2Gilead SciencesNCT03551522Written as Seladelpar
- ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)CompletedPhase 3Gilead SciencesNCT03602560Written as seladelpar 10 mg
- Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)CompletedPhase 2Gilead SciencesNCT02955602Written as MBX-8025 2 mg Capsule
- Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy SubjectsCompletedPhase 1Gilead SciencesNCT03369002Written as seladelpar
- Study to Evaluate the Effects of MBX-8025 in Patients With HoFHCompletedPhase 2Gilead SciencesNCT02472535Written as MBX-8025 50 mg (Dose Escalation Period 1)
- Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High CholesterolCompletedPhase 2Gilead SciencesNCT00701883Written as MBX-8025
Codes
What other systems call seladelpar · ClinicalTrials.gg INT001553
- MeSH (NLM) C000713688seladelparConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7C00L34NB9SELADELPARConfirmed FDA, NLM, Wikidata
- Wikidata Q27268037seladelparConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C167015SeladelparOne source FDA
- DrugBank DB12390One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000713688 | seladelpar | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7C00L34NB9 | SELADELPAR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27268037 | seladelpar | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C167015 | Seladelpar | One source FDA |
| DrugBank | DB12390 | — | One source Wikidata |
Also registered as seladelpar lysine (UNII N1429130KR).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.